AAP
CMPX icon

Arax Advisory Partners’s Compass Therapeutics CMPX Stock Holding History

Arax Advisory Partners’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18
Closed -$97 – 3899
2025
Q4 		$97 Sell
18
-207
-92% -$956 ﹤0.01% 3828
2025
Q3 		$787 Buy
+225
New +$711 ﹤0.01% 3304

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Arax Advisory Partners's CMPX Position: Q1 2026 in Review

Arax Advisory Partners sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 18 shares — an estimated $97 sold.

Arax Advisory Partners first reported a position in CMPX in Q3 2025 and held it in 2 quarters. The position peaked at $787 in Q3 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Arax Advisory Partners reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 18 Compass Therapeutics shares in Q1 2026, an estimated $97.
  • Arax Advisory Partners first reported a position in Compass Therapeutics in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Compass Therapeutics position peaked at $787 in Q3 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.